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Abstract
Although genome-wide association studies (GWAS) have separately identified many genetic susceptibility loci for 
ulcerative colitis (UC), Crohn’s disease (CD) and colorectal cancer (CRC), there has been no large-scale examination for 
pleiotropy, or shared genetic susceptibility, for these conditions. We used logistic regression modeling to examine the 
associations of 181 UC and CD susceptibility variants previously identified by GWAS with risk of CRC using data from the 
Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry. We also examined 
associations of significant variants with clinical and molecular characteristics in a subset of the studies. Among 11 794 CRC 
cases and 14 190 controls, rs11676348, the susceptibility single nucleotide polymorphism (SNP) for UC, was significantly 
associated with reduced risk of CRC (P = 7E−05). The multivariate-adjusted odds ratio of CRC with each copy of the T 
allele was 0.93 (95% CI 0.89–0.96). The association of the SNP with risk of CRC differed according to mucinous histological 
features (Pheterogeneity = 0.008). In addition, the (T) allele was associated with lower risk of tumors with Crohn’s-like reaction 
but not tumors without such immune infiltrate (Pheterogeneity = 0.02) and microsatellite instability-high (MSI-high) but not 
microsatellite stable or MSI-low tumors (Pheterogeneity = 0.03). The minor allele (T) in SNP rs11676348, located downstream 
from CXCR2 that has been implicated in CRC progression, is associated with a lower risk of CRC, particularly tumors 
with a mucinous component, Crohn’s-like reaction and MSI-high. Our findings offer the promise of risk stratification of 
inflammatory bowel disease patients for complications such as CRC. 
Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD), collectively 
known as inflammatory bowel disease (IBD), are chronic inflam-
matory disorders of the gastrointestinal tract that are associ-
ated with an increased risk of colorectal cancer (CRC). The risk 
of CRC appears to increase with the duration, severity and ana-
tomic extent of colonic inflammation (1–3). As a result, individu-
als with greater than a 8 to 12-year history of IBD are currently 
recommended to undergo annual colonoscopy with surveillance 
biopsies or chromoendoscopy with targeted biopsies to screen 
for precancerous and cancerous changes (4). Despite this com-
pelling evidence for the association between IBD and CRC, there 
are no data on the potential for pleiotropy or shared genetic sus-
ceptibility between these conditions.
Genome-wide association (GWA) studies have identified 
more than 180 risk loci that are associated with risk of CD and 
UC (5–7). A  number of these variants with potential biologic 
significance have shown to be associated with other chronic 
inflammatory disorders (5), and such studies previously led 
to identification of new and novel therapies for IBD (8–10). We 
therefore sought to establish whether known susceptibility vari-
ants for UC and CD are also associated with risk of CRC using 
data from the Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO) and the Colon Cancer Family Registry 
(CCFR) (11). In addition, we explored the potential functional 
significance of candidate variants with pleiotropic effect by 
examining their association with clinical and molecular charac-
teristics of CRC using cases for which we had collected tissue for 
histologic and molecular analyses.
Methods
Study participants
Each study is described in detail in the Supplementary Material, available 
at Carcinogenesis Online and the number of cases and controls, as well as 
Abbreviations  
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HPFS Health Professional Follow up Study 
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the age and sex distributions is listed in Supplementary Table  1, avail-
able at Carcinogenesis Online. In brief, CRC cases were defined as men and 
women diagnosed with colorectal adenocarcinoma and confirmed by 
medical records, pathologic reports, cancer registries or death certificates. 
All participants provided informed consent; each study was approved by 
their respective Institutional Review Boards.
Genotyping
GWAS in GECCO and CCFR
We conducted a meta-analysis of 181 previously identified IBD risk variants 
in 14 studies within the GECCO and the CCFR (11 794 cases and 14 190 con-
trols). Details regarding genotyping and data quality control are described 
elsewhere (12). Owing to limited numbers, we did not analyze samples 
clustering with other HapMap populations (e.g. YRI), retaining those that 
clustered with the Utah Residents with Northern and Western European 
Ancestry (CEU) population and adjusting for population stratification using 
principle component analysis (See Statistical Analysis). Genotyped single 
nucleotide polymorphisms (SNPs) were excluded based on call rate (<98%), 
lack of Hardy Weinberg Equilibrium in controls (P < 1 × 10–4), and low minor 
allele frequency <5%. As imputation of genotypes is established as stand-
ard practice in the analysis of genotype data, we imputed the autosomal 
SNPs of all studies to the CEU population in HapMap II. Imputed SNPs were 
restricted based on minor allele frequency (≥1%) and imputation accuracy 
(R2 > 0.3). In our detailed result table (Supplementary Table 2, available at 
Carcinogenesis Online), we list for each SNP the number of studies with 
directly genotyped or imputed data and the mean imputation R2. These data 
show, as expected, that imputed SNPs tend to show very similar results to 
SNPs that were directly genotyped if the correlation is high between SNPs. 
The IBD SNPs were selected based on the most recent results of CD and UC 
genome-wide association studies (GWAS) (6,7,13). The risk allele is defined 
as the allele with reported association with CD or UC.
Pathological assessment of molecular characteristics
Beginning in 1997 in the Health Professional Follow up Study (HPFS) and 
2001 in the Nurses’ Health Study (NHS), we began retrieving specimens from 
the pathology departments of treating hospitals for participants with con-
firmed diagnosis of CRC (14). Histological features including degree of differ-
entiation, presence of mucinous, signet cell components, tumor infiltrating 
lymphocytes, or Crohn’s disease-like reaction and tumor growth pattern 
were collected by a pathologist (S.O.) as described previously (15,16). Real-
time PCR (MethyLight) was used for quantitative DNA methylation to deter-
mine CpG island methylator phenotype (CIMP) status using DNA extracted 
from paraffin-embedded tissue (17). We quantified DNA methylation in eight 
CIMP-specific promoters as detailed elsewhere (18). CIMP-high was defined 
as ≥6/8 methylated markers using the eight-marker CIMP panel, and CIMP-
low/negative was defined as 0/8 to 5/8 methylated markers, according to 
previously established criteria (19). Microsatellite instability (MSI) analysis 
was performed using 10 microsatellite markers (D2S123, D5S346, D17S250, 
BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and D18S487). MSI-high was 
defined as the presence of instability in ≥30% of the markers, and MSI-low/
microsatellite stable (MSS) as instability in 0–29% of markers (20). We per-
formed PCR and pyrosequencing targeted for KRAS (codons 12 and 13) and 
BRAF (codon 600) (20,21). TP53 and CDX2 expression were assessed by immu-
nohistochemistry as detailed elsewhere (22,23).Tumor molecular phenotype 
was previously evaluated in the Diet, Activity, and Lifestyle Study (DALS) 
study for CIMP and MSI status, BRAF, TP53 and KRAS mutations using meth-
ods that have been described previously in detail (24–27).
Statistical analysis
GWAS in GECCO and CCFR
For each study, we estimated the association between SNPs and risk of 
CRC by calculating betas, odds ratios (ORs), standard errors, 95% confi-
dence intervals (CIs) and P values using logistic regression models with 
log-additive genetic effects. Each directly genotyped SNP was coded as 0, 
1 or 2 copies of the risk allele. For imputed SNPs, we used the expected 
number of copies of the risk allele (the ‘dosage’), which has been shown to 
give unbiased estimates in the association test for imputed SNPs (28). We 
adjusted for age, sex (when appropriate), study center (when appropriate), 
batch effects (ASTERISK only) and the first three principal components 
from EIGENSTRAT to account for population substructure. As CCFR Set 2 is 
a family-based study, we used logistic regression model stratified by fam-
ily ID while adjusting for age and sex.
We conducted inverse-variance weighted, fixed-effects meta-anal-
yses to combine beta estimates and standard errors across individual 
studies. In this approach, we weighted the beta estimate of each study 
by the inverse of its variance, and calculated a combined estimate by 
summing the weighted betas and dividing by the summed weights. For 
imputed SNPs, it has been shown that the inverse variance is approxi-
mately proportional to the imputation quality (28). Thus, the inverse vari-
ance weighting scheme automatically incorporates imputation quality in 
the meta-analysis for imputed SNPs. We calculated the heterogeneity P 
values based on Cochran’s Q statistic (29). Bonferroni-adjusted P value of 
2.8E−04 (=0.05/181) was considered statistically significant. We used PLINK 
(30) and R to conduct the statistical analysis of the SNP and CRC associa-
tions across studies.
Characterization of variant shown to be associated with CRC 
(rs11676348)
Within the NHS and HPFS, we used logistic regression to estimate OR 
and corresponding 95% CI for the association of variant rs11676348 with 
CRC stratified by tumor phenotype (poorly differentiated tumors versus 
moderately well differentiated tumors), tumor histology (presence versus 
absence of mucinous, signet cell, Crohn’s-like reaction, tumor infiltrating 
lymphocytes or peritumor lymphocytic reaction, and expansible versus 
intermediate/infiltrative tumor growth pattern) and molecular charac-
teristics (mutant versus wild-type KRAS; mutant versus wild-type BRAF; 
MSI-H versus MSI-L/MSS; CIMP-low/negative versus CIMP-high; presence 
versus absence of TP53 and CDX2 expressions). Because there was no het-
erogeneity for the association of SNP rs11676348 with CRC risk between 
women and men (P for heterogeneity > 0.40), we pooled data from the 
two studies of NHS and HPFS. To assess the effect of rs11676348 on CRC 
according to clinical phenotype or molecular characteristics in NHS/HPFS, 
we used a case–case logistic regression model comparing tumor subtypes. 
We used similar analyses to validate our findings with regards to the effect 
of variant rs11676348 on CRC according to molecular characteristics (CIMP 
and MSI status, BRAF, TP53 and KRAS mutations) in DALS. We used SAS 
V9.2 (SAS Institute, Cary, NC) for the analysis related to the characteriza-
tion of variant rs11676348 and tumor subtypes in NHS/HPFS and DALS.
Results
Among 11 794 CRC cases and 14 190 controls, we examined 181 
SNPs previously associated with risk of UC and CD in relation 
to risk of CRC. Among these SNPs, we identified rs11676348, a 
susceptibility SNP for UC, as significantly inversely associated 
with risk of CRC (P = 7E−05) after Bonferroni correction for mul-
tiple comparisons (Figure 1). The mean allele frequency for the 
(T) allele was 0.50 with a range of 0.46–0.54 among the stud-
ies. The multivariate-adjusted odds ratio (OR) of CRC with each 
copy of minor allele (T) for rs11676348 was 0.93 (95% CI 0.89–
0.96) (Figure 2). There was no statistically significant heteroge-
neity in the association among studies (Pheterogeneity  =  0.81). We 
also observed that rs102275, a susceptibility loci for CD located 
in TMEM258 gene on chromosome 11, was inversely associated 
with risk of CRC (OR = 0.92, 95% CI 0.88–0.96, P = 2E−05). However, 
because of heterogeneity among the studies (Pheterogeneity = 0.09), 
the variant did not meet the Bonferroni-corrected significance 
using random-effect meta-analysis (P = 4E−04).
To explore the possibility that the association between 
rs11676348 and risk of CRC is mediated by clinical diagnosis 
of UC or CD, we performed sensitivity analyses limiting our 
meta-analysis to the 11 studies with available data on reported 
diagnoses of UC and CD and excluded those with self-reported 
diagnosis of UC or CD (Supplementary Table  3, available at 
Carcinogenesis Online). Among 9963 cases and 12 285 controls, we 
observed a consistent association of the (T) allele in rs11676348 
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with a lower risk of CRC (multivariate-adjusted OR  =  0.93, 
P = 8.3E−04).
We explored the possibility that the inverse association of 
this UC susceptibility SNP with CRC may be limited to specific 
molecular subtypes of CRCs. Among 293 CRC cases with avail-
able molecular and histologic characteristics and 1172 con-
trols in NHS/HPFS, the association of rs11676348 SNP with CRC 
appeared to vary according to MSI status (Pheterogeneity  =  0.03), 
presence of mucinous component (Pheterogeneity  =  0.008) and 
Crohn’s-like reaction within the tumor (Pheterogeneity = 0.02) (Tables 
1 and 2). The (T) allele at the UC susceptibility locus rs11676348 
was associated with a lower risk of MSI-H CRC (multivariate OR 
0.57; 95% CI 0.33–0.99) but not MSS/MSI-L CRC (multivariate-
adjusted OR 1.05, 95% CI 0.86–1.29). Similarly, the (T) allele was 
associated with a lower risk of mucinous CRC (multivariate OR 
0.77; 95% CI 0.58–1.02) but not CRC without a mucinous com-
ponent (multivariate OR 1.21; 95% CI 0.96–1.52;). Finally, the (T) 
allele was associated with a lower risk of CRC with the presence 
Figure 1. Association between known IBD variants and risk of colorectal cancer. Manhattan plot of the meta-analysis association between risk variants of Crohn’ dis-
ease (CD) and ulcerative colitis (UC) and colorectal cancer. Each association is colored according to disease (CD or UC) for which the single nucleotide polymorphism 
was originally reported, and positioned on the x-axis according to its genomic position. Filled circles represent the results of fixed effect meta-analysis while blank 
circles reflect results of random effect meta-analysis. 
Figure 2. Meta-analysis of association of rs11676348 SNP with CRC.
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of a Crohn’s-like reaction (multivariate OR 0.68; 95% CI 0.47–
0.99) but not CRC without a Crohn’s-like reaction (multivariate 
OR 1.11; 95% CI 0.90–1.37). The association of the (T) allele with 
risk of CRC did not appear to differ according to other histo-
logic or molecular characteristics including presence of a signet 
cell component or peritumoral lymphocytic reaction, tumor dif-
ferential or growth, CIMP status, expression of CDX2 or TP53 or 
mutations in BRAF or KRAS.
We also confirmed the association between rs11676348 
and risk of CRC according to molecular subtypes in a separate 
cohort of 548 cases and 728 controls in DALS. Similar to our 
findings in NHS and HPFS, the association of the SNP seemed 
to be modified by MSI status (Pheterogeneity  =  0.03). Compared to 
participants with TT genotype, the risk of developing MSI-H 
CRC among participants with CT and TT genotypes were 0.67 
(95% CI 0.41–1.11) and 0.52 (95% CI 0.26–1.03), respectively 
(Ptrend  =  0.04). Conversely, compared to participants with TT 
genotype, the risk of developing MSI-L/MSS CRC among partici-
pants with CT and TT genotypes were 1.14 (95% CI 0.86–1.50) 
and 1.16 (95% CI 0.83–1.63), respectively (Ptrend = 0.37). The asso-
ciation of the (T) allele with risk of CRC did not appear to differ 
according to CIMP status, expression of CDX2, or mutations in 
BRAF, TP53, or KRAS genes.
Discussion
In this large meta-analysis of individual-level data that included 
11 794 cases of CRC and 14 190 controls, we examined the asso-
ciation of GWAS-identified risk variants for UC and CD on risk 
of CRC. We identified that the (T) allele in rs11676348, a UC sus-
ceptibility locus located on chromosome 2, to be inversely asso-
ciated with risk of CRC. In addition, using a subgroup of CRC 
cases with known histologic and molecular data, we showed 
that rs11676348 was particularly associated with lower risk of 
CRC tumors with Crohn’s-like reaction, MSI-H status and muci-
nous components which are each characteristics of tumors with 
high inflammatory burden. We subsequently confirmed these 
findings in a separate population. Of note, we did not observe 
an association between rs11676348 and CRC cases with peritu-
moral lymphocytic reaction, which is typically associated with 
mucinous and MSI-H tumors. The lack of association is probably 
due to presence of at least mild lymphocytic reaction in most of 
our cases (>80%), consistent with previous reports (31,32).
Our findings are supported by biologically plausible mech-
anisms. rs11676348 was identified in GWAS of UC to be cor-
related with expression of CXCR2 gene (from whole blood 
samples) through analyses of expression quantitative trait 
Table 1. Associations between rs11676348 variant and risk of CRC according to histologic subtypesa
Controls Cases OR (95% CI) Cases OR (95% CI) Pheterogeneity
b
Mucinous component (−) Mucinous component (+)
CC 287 47 1 42 1 0.008
CT 616 70 0.67 (0.45–1.00) 51 0.56 (0.36–0.87)
TT 269 59 1.34 (0.91–2.12) 24 0.66 (0.38–1.12)
P trend 0.11 0.07
T allele 1.21 (0.96–1.52) 0.77 (0.58–1.02)
Crohn’s-like reaction (−) Crohn’s-like reaction (+)
CC 287 60 1 27 1 0.02
CT 616 93 0.71 (0.49–1.01) 28 0.46 (0.26–0.80)
TT 269 67 1.21 (0.82–1.79) 13 0.55 (0.28–1.11)
P trend 0.33 0.04
T allele 1.11 (0.90–1.37) 0.68 (0.47–0.99)
Tumor infiltrating lymphocytes (−) Tumor infiltrating lymphocytes (+)
CC 287 57 1 30 1 0.05
CT 616 93 0.74 (0.51–1.06) 27 0.40 (0.23–0.70)
TT 269 63 1.21 (0.81–1.81) 18 0.67 (0.36–1.25)
P trend 0.35 0.11
T allele 1.11 (0.89–1.37) 0.75 (0.53–1.06)
Peritumor lymphocytic reaction (−) Peritumor lymphocytic reaction (+)
CC 287 12 1 76 1 0.55
CT 616 21 0.80 (0.39–1.66) 98 0.58 (0.42–0.82)
TT 269 9 0.80 (0.33–1.95) 72 1.05 (0.73–1.53)
P trend 0.61 0.87
T allele 0.89 (0.57–1.40) 1.02 (0.83–1.24)
Well-moderate differentiated Poorly differentiated
CC 287 86 1 6 1 0.54
CT 616 126 0.66 (0.49–0.91) 7 0.51 (0.17–1.55)
TT 269 84 1.08 (0.76–1.53) 4 0.76 (0.21–2.72)
P trend 0.74 0.59
T allele 1.03 (0.86–1.24) 0.82 (0.40–1.68)
Tumor growth (expansible) Tumor growth (intermediate-infiltrative)
CC 287 28 1 28 1 0.94
CT 616 31 0.49 (0.29–0.84) 31 0.49 (0.29–0.84)
TT 269 26 1.05 (0.59–1.86) 26 1.05 (0.59–1.86)
P trend 0.98 0.98
T allele 1.01 (0.73–1.39) 1.01 (0.73–1.39)
aModels were adjusted for age (years), cohort (NHS, HPFS) and the first three eigenvectors.
bCalculated using a case–case only logistic regression model comparing tumor subtypes.
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loci (6). The CXCR2 gene, located 10 kB downstream from 
rs11676348, is a member of G-protein-coupled receptor family 
with high affinity for IL-8. CXCR2 primarily mediates migra-
tion of neutrophils to the site of inflammation and facili-
ties the angiogenic effect of IL-8 in intestinal microvascular 
endothelial cells. More recently, CXCR2 has been implicated in 
development of CRCs associated with chronic colonic inflam-
mation in experimental models. Katoh and colleagues (33) 
showed that loss of CXCR2 dramatically suppresses chronic 
colonic inflammation and colitis-associated tumorigenesis 
through inhibition of the infiltration of myeloid-derived sup-
pressor cells into colonic mucosa and tumors in a mouse 
model of colitis-associated cancer. Similarly, using several 
mouse models of spontaneous and inflammation-driven neo-
plasia, Jamieson and colleagues showed that inhibition of 
CXCR2 profoundly suppresses inflammation-driven tumori-
genesis (34).
Several studies have demonstrated a higher incidence of 
MSI-H in the cancers that develop in the setting of long-stand-
ing UC with severe inflammation (35–37). Specifically, compared 
with MSS stable tumors, MSI-H tumors are characterized by 
a higher inflammatory burden (35,38). Moreover, it has been 
demonstrated that chronic inflammation is associated with an 
imbalance in base excision-repair enzymes that contributes to 
microsatellite instability (39).
In addition to CXCR2, expression quantitative trait loci stud-
ies have linked rs11676348 to expression of MR1 gene (40). MR1 
encodes an antigen-presenting molecule specialized in pre-
senting microbial vitamin B6 metabolites (41,42). The protein 
is also involved in the development and expansion of a small 
population of T-cells expressing an invariant T-cell receptor 
alpha chain called mucosal-associated invariant T-cells (42,43). 
Mucosal-associated invariant T-cells lymphocytes are preferen-
tially located in the gut lamina propria and therefore may be 
Table 2. Associations between rs11676348 variant and risk of CRC according to molecular subtypesa
Controls Cases OR (95% CI) Cases OR (95% CI) Pheterogeneity
b
MSS/MSI-L MSI-H
CC 287 68 1 14 1 0.03
CT 616 99 0.65 (0.46–0.92) 12 0.40 (0.18–0.89)
TT 269 69 1.10 (0.75–1.62) 5 0.42 (0.15–1.18)
P trend 0.65 0.05
T allele 1.05 (0.86–1.29) 0.57 (0.33–0.99)
CIMP-low/negative CIMP-high
CC 287 60 1 15 1 0.32
CT 616 96 0.72 (0.50–1.03) 16 0.50 (0.24–1.04)
TT 269 62 1.12 (0.75–1.67) 10 0.74 (0.33–1.70)
P trend 0.61 0.38
T allele 1.06 (0.86–1.31) 0.82 (0.52–1.29)
BRAF mutation (−) BRAF mutation (+)
CC 287 71 1 12 1 0.21
CT 616 100 0.66 (0.44–0.98) 12 0.53 (0.33–0.86)
TT 269 69 0.94 (0.59–1.48) 7 1.04 (0.63–1.74)
P trend 0.72 0.95
T allele 0.96 (0.75–1.22) 1.01 (0.76–1.34)
KRAS mutation (−) KRAS mutation (+)
CC 287 48 1 35 1 0.92
CT 616 72 0.63 (0.45–0.89) 41 0.47 (0.21–1.06)
TT 269 42 1.05 (0.72–1.55) 33 0.65 (0.25–1.67)
P trend 0.84 0.28
T allele 1.02 (0.83–1.25) 0.75 (0.44–1.26)
CDX2 (+) CDX2 (−)
CC 287 36 1 11 1 0.77
CT 616 47 0.58 (0.37–0.93) 12 0.52 (0.22–1.19)
TT 269 32 0.96 (0.58–1.61) 6 0.59 (0.22–1.63)
P trend 0.81 0.24
T allele 0.97 (0.73–1.28) 0.72 (0.42–1.24)
TP53 expression (−) TP53 expression (+)
CC 287 45 1 22 1 0.06
CT 616 54 0.55 (0.36–0.84) 40 0.81 (0.47–1.40)
TT 269 34 0.81 (0.50–1.30) 30 1.53 (0.85–2.73)
P trend 0.29 0.13
T allele 0.87 (0.67–1.13) 1.27 (0.93–1.74)
aModels were adjusted for age (years), cohort (NHS, HPFS) and the first three eigenvectors.
bCalculated using a case–case only logistic regression model comparing tumor subtypes.
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involved in monitoring commensal flora or serve as a distress 
signal (44,45). These findings may point to novel pathways asso-
ciated with genetic variation that may potentially modify the 
effect of environmental factors (gut commensal bacterial and B 
vitamins) on risk of IBD and CRC (46–48).
The seemingly opposing effects of the (T) allele of rs11676348 
with increased risk of UC but decreased risk of CRC may, at least 
at first, appear inconsistent. However, this SNP may still be a 
marker for shared pathways between UC and CRC that contrib-
ute to the initiation of mucosal inflammation and colitis but 
inhibit carcinogenesis. Similarly, we previously observed that a 
SNP associated with lower incident CRC risk was subsequently 
associated with poorer survival (49). Alternatively, genetic vari-
ation underlying the pathways associated with this SNP may 
predispose to distinctive phenotypic manifestations of a com-
mon mechanism (e.g. chronic inflammation versus cancer). The 
large number of subjects and the consistency of our observed 
associations across 14 separate, well-characterized studies add 
strength to our findings. In addition, we were able to deploy 
molecular pathological epidemiology approach to provide 
evidence for a role of the risk variant in specific pathogenic 
mechanisms (50). Indeed, the consistency of our associations 
with specific molecular and histological subtypes of CRC within 
two distinct studies provides additional evidence of a true 
association.
Limitations of our study include inclusion of only European 
ancestry participants. In addition, it is possible that a higher 
prevalence of IBD patients among the CRC cases may account 
for our observed associations. However, this is unlikely for sev-
eral reasons. First, our sensitivity analyses excluding cases of 
IBD from our case–control set did not materially alter our effect 
estimates. Second, considering the low prevalence of IBD among 
cases and controls (<0.5%) together with the observation that 
other SNPs that are more strongly associated with risk of UC and 
CD were not found to be associated with risk of CRC, we believe 
that such oversampling is unlikely to have biased our results. 
Third, if the association between rs11676348 and CRC was medi-
ated by its association with UC, we would expect that direction-
ality of the association to be the same. In contrast, we observed 
that the T allele associated with UC was inversely associated 
with risk of CRC. Finally, as more recent GWAS have identified 
new IBD risk loci, these variants remain to be evaluated for their 
pleiotropic effects with CRC.
In conclusion, we identified a UC susceptibility locus, 
rs11676348, with pleotropic effect on risk of CRC. Our findings 
highlight the potential importance of common pathways under-
lying risk of IBD and CRC and have compelling biological plau-
sibility as this SNP is in close proximity to CXCR2 and is more 
strongly associated with risk of specific subtypes of CRC (Crohn’s 
like-reaction, mucinous component or MSI-H status) that may 
have a distinct molecular pathogenesis associated with either 
CXCR2 function or chronic inflammation. Our finding further 
strengthens the potential importance of CXCR2-mediated path-
ways in inflammation and tumorigenesis. Whether these find-
ings can be generalized to individuals with established IBD is 
unknown and yet to be determined. However, our finding pro-
vides proof-of-principle that genetic susceptibility loci could 
potentially be used to risk-stratify individuals with IBD for the 
development of CRC.
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